Skip Navigation

European Journal of Heart Failure 2007 9(3):306-309; doi:10.1016/j.ejheart.2006.06.005
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Francia, P.
Right arrow Articles by Volpe, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Francia, P.
Right arrow Articles by Volpe, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society of Cardiology

Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin

Pietro Franciaa,*, Adriano Salvatia, Cristina Ballaa, Paola De Paolisd, Erika Pagannonea, Marina Borrob, Giovanna Gentileb, Maurizio Simmacob, Luciano De Biasea and Massimo Volpea,c

a Division of Cardiology 2nd Faculty of Medicine, University "La Sapienza", Sant'Andrea Hospital, Rome, Italy
b DiMA Laboratory 2nd Faculty of Medicine, University "La Sapienza", Sant'Andrea Hospital, Rome, Italy
c IRCCS Neuromed Pozzilli (IS), Italy
d Research Center, AFaR San Pietro Hospital FbF, Rome, Italy

* Corresponding author. Tel.: +39 06 33 77 55 61; fax: +39 06 33 77 50 61. E-mail address: p.francia{at}tiscali.it


   Abstract

Background: Cardiac resynchronization therapy (CRT) has been introduced to treat drug refractory chronic heart failure (CHF). Apelin, the endogenous ligand of the APJ receptor, is under evaluation for its potential role in human CHF pathophysiology. This study aims to assess whether biventricular pacing affects plasma apelin levels in patients with severe CHF.

Methods and results: Fourteen patients (9 men, 5 women, mean age 68±13years) undergoing biventricular pace-maker/ICD implantation were studied. Patients underwent baseline clinical and echocardiographic evaluation, and assessment of plasma apelin and NT-proBNP levels. The evaluation was repeated 48h and 9±2months after device implantation to assess the acute and chronic effects of CRT on apelin and NT-proBNP levels. Eight healthy age- and sex-matched subjects served as controls.

In CHF patients, baseline apelin levels were reduced and NT-proBNP increased compared to control subjects (apelin: 0.47±0.2 vs. 0.97±0.3ng/mL, p<0.001; NT-proBNP: 2007±114 vs. 229±72pmol/L, p<0.001). Short-term evaluation did not reveal any effect of CRT on apelin or NT-proBNP levels. By contrast, at 9±2months follow-up, CRT responders showed left ventricular reverse remodelling and an increase in ejection fraction, together with a significant increase in plasma apelin levels (0.99±0.1 vs. 0.47±0.2ng/mL, p<0.001) and decrease in NT-proBNP (938±591 vs. 2007±114pmol/L, p<0.05).

Conclusions: Long-term CRT increases plasma levels of the endogenous inotrope apelin in patients with CHF.

Key Words: Apelin • Resynchronization • Heart failure • NT-proBNP • APJ • Neurohormones

Received February 20, 2006; Revised May 1, 2006; Accepted June 15, 2006


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Eur J Heart FailHome page
R. A.P. Weir, K. S. Chong, J. R. Dalzell, C. J. Petrie, C. A. Murphy, T. Steedman, P. B. Mark, T. A. McDonagh, H. J. Dargie, and J. J.V. McMurray
Plasma apelin concentration is depressed following acute myocardial infarction in man
Eur J Heart Fail, June 1, 2009; 11(6): 551 - 558.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
B. Chandrasekaran, O. Dar, and T. McDonagh
The role of apelin in cardiovascular function and heart failure
Eur J Heart Fail, August 1, 2008; 10(8): 725 - 732.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.